Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Week-Long heart patch catch more dangerous rhythms than a One-Day test?

NCT ID NCT06310707

Diagnosis Sponsor: Philips Clinical & Medical Affairs Global Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether wearing a small, waterproof heart monitor (ePatch) for 7 days finds more treatable heart rhythm problems than the usual 24-hour Holter monitor in people who have fainted. About 55 adults with fainting symptoms were randomly assigned to either the 7-day ePatch or a standard 24-hour monitor. The goal was to see if the longer monitoring period leads to more diagnoses that can guide treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ePatch Extended Wear Holter (7-day heart monitor)
What this could lead to
If successful, this could show that longer monitoring with ePatch finds more treatable heart rhythm problems than the standard 24-hour test.
What could go wrong
The study was terminated early with only 55 participants, so results may be limited. Longer monitoring may also pick up harmless findings that lead to unnecessary worry or tests.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

55 people

The number who actually took part.

Started

Nov 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years old 2. Recommended for ambulatory cardiac Holter monitoring due to symptoms of syncope 3. Able to comply with continuous ECG monitoring for up to 7 days 4. Able and willing to replace the Patch electrode at home 5. Capable of providing voluntary informed consent and mentally and physically willing and able to be compliant with the protocol, including the follow-up visit(s) Exclusion Criteria: 1. Patient with chronic Atrial Fibrillation (AF) 2. Patient with implanted pacemaker/defibrillator 3. Patient with known allergy to adhesive materials and/or hydrogel 4. Patient with broken, damaged, or irritated skin where ECG patch will be placed

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arrythmia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac cardiac rhythm disease Syncope syncope, familial vasovagal

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arrythmia Syncope

Contacts and locations

Locations

  • Deutsches Herzzentrum der Charité (DHZC) - Campus Benjamin Franklin

    Berlin, D-12203, Germany

  • Hospices Civils de Lyon - Hôpital Cardiologique Louis Pradel

    Bron, 69677 Cedex, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.